Join our daily newsletter At The Bell to receive exclusive market insights
- TruScreen Group says its China-based cervical cancer screening trial has validated the company’s screening method
- The three-year study screened 15,661 women aged 21 years and older in a clinical setting across 64 teaching hospitals in nine Chinese provinces
- The study compared the relative effectiveness of TruScreen’s method against two other cervical cancer screening methods of HPV DNA testing and Liquid Based Cytology (LBC)
- The company says results determined TruScreen is a simple, effective and rapid real-time method to screen for cervical cancer
- COGA concluded the study highlights the “superiority” of TruScreen’s screening method and that it was an appropriate primary screening tool in regions with high morbidity and mortality of cervical cancer
- TRU shares last traded at six cents on April 4
TruScreen Group (TRU) has announced its China-based cervical cancer screening trial validated the company’s screening method.
The company said the Chinese Obstetricians and Gynaecologists Association (COGA) last year completed the detailed almost three-year cervical cancer screening trial involving the screening of 15,661 women aged 21 years and older in a clinical setting across 64 teaching hospitals in nine Chinese provinces.
The study compared the relative effectiveness of TruScreen’s method against two other cervical cancer screening methods of HPV DNA testing and Liquid Based Cytology (LBC).
Results indicated TruScreen was a simple, effective and rapid real-time method to screen for cervical cancer and also highlighted the advantage of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-testing.
All the women participants in the trial underwent primary screening with TruScreen, HPV and LBC, where levels of sensitivity and specificity were computed.
Results showed TruScreen’s sensitivity was well above that for LBC (87.5 per cent versus 66.5 per cent), while TruScreen’s specificity of 88.4 per cent was higher than both LBC (86.3 per cent) and HPV testing (78.3 per cent).
COGA concluded the study pointed to the “superiority” of TruScreen’s screening method and that it was an appropriate primary screening tool in regions with high morbidity and mortality of cervical cancer.
TRU shares last traded at six cents on April 4.
